EA202192776A1 - Схемы введения доз и композиции, включающие антитела к rsv - Google Patents

Схемы введения доз и композиции, включающие антитела к rsv

Info

Publication number
EA202192776A1
EA202192776A1 EA202192776A EA202192776A EA202192776A1 EA 202192776 A1 EA202192776 A1 EA 202192776A1 EA 202192776 A EA202192776 A EA 202192776A EA 202192776 A EA202192776 A EA 202192776A EA 202192776 A1 EA202192776 A1 EA 202192776A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rsv
present
invention describes
compositions including
including antibodies
Prior art date
Application number
EA202192776A
Other languages
English (en)
Russian (ru)
Inventor
Анис Ахмед Хан
Вадрин Пьерр
Original Assignee
Медиммун Лимитед
Санофи Пастер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед, Санофи Пастер Инк. filed Critical Медиммун Лимитед
Publication of EA202192776A1 publication Critical patent/EA202192776A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
EA202192776A 2019-04-30 2020-04-30 Схемы введения доз и композиции, включающие антитела к rsv EA202192776A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Publications (1)

Publication Number Publication Date
EA202192776A1 true EA202192776A1 (ru) 2022-01-19

Family

ID=70779897

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192776A EA202192776A1 (ru) 2019-04-30 2020-04-30 Схемы введения доз и композиции, включающие антитела к rsv

Country Status (15)

Country Link
US (3) US12024553B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962940A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022531205A (cg-RX-API-DMAC7.html)
KR (1) KR20220002427A (cg-RX-API-DMAC7.html)
CN (1) CN113825767A (cg-RX-API-DMAC7.html)
AU (1) AU2020265676A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021020846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014370A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192776A1 (cg-RX-API-DMAC7.html)
IL (1) IL287443A (cg-RX-API-DMAC7.html)
MX (1) MX2021013248A (cg-RX-API-DMAC7.html)
SG (1) SG11202111748TA (cg-RX-API-DMAC7.html)
TW (1) TWI861099B (cg-RX-API-DMAC7.html)
WO (1) WO2020223435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20240055097A (ko) * 2021-09-13 2024-04-26 메디뮨 리미티드 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방
EP4588936A4 (en) * 2022-12-08 2026-08-12 Changchun Bcht Biotechnology Co ANTIBODIES THAT BIND SPECIFICALLY TO VRS
CN121846262A (zh) * 2026-01-05 2026-04-14 上海生物制品研究所有限责任公司 抗呼吸道合胞病毒单克隆抗体制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤

Also Published As

Publication number Publication date
TW202106333A (zh) 2021-02-16
MX2021013248A (es) 2022-01-24
WO2020223435A1 (en) 2020-11-05
EP3962940A1 (en) 2022-03-09
CA3138180A1 (en) 2020-11-05
BR112021020846A2 (pt) 2022-01-18
JP2025072444A (ja) 2025-05-09
IL287443A (en) 2021-12-01
US20220204593A1 (en) 2022-06-30
US12024553B2 (en) 2024-07-02
US20200347120A1 (en) 2020-11-05
KR20220002427A (ko) 2022-01-06
US20240417447A1 (en) 2024-12-19
CN113825767A (zh) 2021-12-21
JP2022531205A (ja) 2022-07-06
AU2020265676A1 (en) 2021-11-18
CO2021014370A2 (es) 2021-10-29
TWI861099B (zh) 2024-11-11
SG11202111748TA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
ZA202202363B (en) Antibodies against ilt2 and use thereof
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
GEAP202114794A (en) Antibody neutralizing human respiratory syncytial virus
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
UA94899C2 (ru) Фиксированное дозирование антител к her
EA201990988A1 (ru) Антитела против chikv и пути их применения
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
GEAP202516662A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
EA202091747A1 (ru) Составы антитела b7-h4
RU2011142183A (ru) Средство для лечения ревматоидного артрита
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
MY209791A (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EA201100884A1 (ru) Моноклональные антитела анти-rhd
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.
EA201990222A1 (ru) Антитела к o2 и пути их применения
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
RU2017135005A (ru) Фармацевтическая композиция для лечения и/или предотвращения злокачественной опухоли